Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDNANYSE:RFLNASDAQ:VRCANASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsRFLRafael$1.74+1.8%$1.84$1.29▼$2.50$43.35M0.9932,633 shs43,748 shsVRCAVerrica Pharmaceuticals$0.49+4.8%$0.56$0.38▼$11.41$44.89M1.68582,926 shs273,557 shsXLOXilio Therapeutics$0.83-1.1%$0.81$0.62▼$1.70$42.90M-0.251.18 million shs125,027 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%RFLRafael+2.72%+1.80%-17.87%-19.96%-0.58%VRCAVerrica Pharmaceuticals+1.70%-4.89%-2.14%-35.46%-93.13%XLOXilio Therapeutics+5.55%+11.50%+10.26%+2.18%-20.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDNAMedicenna Therapeutics1.1301 of 5 stars3.50.00.00.00.01.70.0RFLRafael0.4788 of 5 stars0.02.00.00.02.40.80.6VRCAVerrica Pharmaceuticals3.3421 of 5 stars3.11.00.04.70.03.30.6XLOXilio Therapeutics2.082 of 5 stars3.53.00.00.00.70.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideRFLRafael 0.00N/AN/AN/AVRCAVerrica Pharmaceuticals 2.20Hold$9.501,842.34% UpsideXLOXilio Therapeutics 3.00Buy$4.00382.80% UpsideCurrent Analyst Ratings BreakdownLatest MDNA, VRCA, RFL, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ARFLRafael$706K61.40N/AN/A$3.51 per share0.50VRCAVerrica Pharmaceuticals$7.57M5.93N/AN/A$0.47 per share1.04XLOXilio Therapeutics$6.34M6.76N/AN/A$1.34 per share0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ARFLRafael-$34.41M-$2.11N/A∞N/A-5,707.03%-53.71%-48.78%6/13/2025 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.54N/AN/AN/A-625.06%-591.84%-141.63%5/12/2025 (Estimated)XLOXilio Therapeutics-$76.40M-$1.28N/AN/AN/AN/A-211.50%-80.31%5/13/2025 (Estimated)Latest MDNA, VRCA, RFL, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025XLOXilio Therapeutics$0.10N/AN/AN/AN/AN/A5/12/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.10N/AN/AN/A$2.53 millionN/A3/13/2025Q2 2025RFLRafaelN/A-$0.06N/A$0.07N/A$0.08 million3/11/2025Q4 2024VRCAVerrica Pharmaceuticals-$0.25-$0.24+$0.01-$0.24$1.30 million$0.34 million3/11/2025Q4 2024XLOXilio Therapeutics-$0.22-$0.20+$0.02-$0.20$2.26 million$1.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ARFLRafaelN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDNAMedicenna TherapeuticsN/A9.579.57RFLRafaelN/A9.749.74VRCAVerrica PharmaceuticalsN/A1.341.22XLOXilio TherapeuticsN/A1.671.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDNAMedicenna Therapeutics12.38%RFLRafael11.30%VRCAVerrica Pharmaceuticals42.45%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipMDNAMedicenna Therapeutics33.10%RFLRafael10.20%VRCAVerrica Pharmaceuticals42.60%XLOXilio Therapeutics5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableRFLRafael2024.91 million22.16 millionOptionableVRCAVerrica Pharmaceuticals4091.78 million26.18 millionOptionableXLOXilio Therapeutics7051.77 million41.67 millionNot OptionableMDNA, VRCA, RFL, and XLO HeadlinesRecent News About These CompaniesXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingApril 23 at 5:09 PM | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comXilio Therapeutics reports Q4 EPS (20c) vs (64c) last yearMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics files $250M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comXilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comXilio Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | finanznachrichten.deXilio Therapeutics Shares Surge Premarket on AbbVie DealFebruary 12, 2025 | marketwatch.comAbbVie, Xilio Hook upFebruary 12, 2025 | baystreet.caAbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager dealFebruary 12, 2025 | fiercebiotech.comAbbVie expands oncology R&D with Xilio dealFebruary 12, 2025 | thepharmaletter.comXilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | globenewswire.comAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesFebruary 12, 2025 | prnewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 3, 2025 | globenewswire.comXilio shares tumble after mixed vilastobart dataJanuary 24, 2025 | thepharmaletter.comWhy Did Chardan Capital Markets Give Xilio Therapeutics Inc (XLO) Stock Buy Rating?January 24, 2025 | bovnews.comXilio reports results from ongoing Phase 2 clinical trial of vilastobartJanuary 23, 2025 | markets.businessinsider.comXilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerJanuary 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDNA, VRCA, RFL, and XLO Company DescriptionsMedicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Rafael NYSE:RFL$1.74 +0.03 (+1.75%) Closing price 03:59 PM EasternExtended Trading$1.73 -0.01 (-0.57%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.Verrica Pharmaceuticals NASDAQ:VRCA$0.49 +0.02 (+4.84%) Closing price 04:00 PM EasternExtended Trading$0.50 +0.02 (+3.25%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Xilio Therapeutics NASDAQ:XLO$0.83 -0.01 (-1.13%) Closing price 04:00 PM EasternExtended Trading$0.82 -0.01 (-1.51%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
